NYSE: RCUSArcus Biosciences Inc Stock
$8.75+0.62 (+7.63%)
Updated Apr 30, 2025
RCUS Price
$8.75
Fair Value Price
N/A
Market Cap
$926.11M
52 Week Low
$6.50
52 Week High
$18.98
P/E
-2.79x
P/B
1.91x
P/S
5.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$258.00M
Earnings
-$283.00M
Gross Margin
100%
Operating Margin
-107.75%
Profit Margin
-109.7%
Debt to Equity
1.37
Operating Cash Flow
-$170M
Beta
1.43
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RCUS Overview
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company tdeveloping cancer therapies. The company's product pipeline Etrumadenant, Zimberelimab, and Domvanalimab, the latter of which targets first-line metastatic non-small cell lung cancer. Arcus Biosciences was incorporated in 2015 and is headquartered in Hayward, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RCUS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RCUS
Ranked#318 of 462
Ranked#318 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important RCUS news, forecast changes, insider trades & much more!
RCUS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RCUS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RCUS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RCUS is good value based on its book value relative to its share price (1.91x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
RCUS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RCUS due diligence checks available for Premium users.
Valuation
RCUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.79x
Industry
-162.28x
Market
29.18x
RCUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.91x
Industry
4.45x
RCUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RCUS's financial health
Profit margin
Revenue
$26.0M
Net Income
-$94.0M
Profit Margin
-361.5%
RCUS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RCUS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$665.0M
Debt to equity
1.37
RCUS's short-term assets ($1.02B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RCUS's short-term assets ($1.02B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RCUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RCUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$100.0M
Investing
$51.0M
Financing
-$2.0M
RCUS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RCUS vs Biotech Stocks
Arcus Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.